Hikma Pharmaceuticals

HIK Ordinary GBP 0.10
Create an alert
Sell1,575.00p
Buy1,577.00p
No change
Last updated today at 06:56 UTC
Back to dashboard

Company Information

About this company

Hikma Pharmaceuticals PLC is a multinational pharmaceutical company engaged in the development, manufacturing and marketing of a broad range of generic, branded and specialty pharmaceutical products. Its pharmaceutical operations are conducted through three business segments: Injectables, Branded and Hikma Rx. It supplies hospitals across North America, Europe and the Middle East and North Africa (MENA) region with generic injectable and specialty medicines, supported by its growing global manufacturing network. It supplies branded generic and in-licensed products from its local manufacturing facilities to retail and hospital customers across the MENA region. Through Hikma Rx, it supplies oral, respiratory and other generic and specialty products to the North American market. Its manufacturing facilities in the United States (US) supply products across a broad range of therapeutic areas, including respiratory, oncology and pain management, serving customers in both the US and Canada.

Key people

Victoria Mary Hull
Independent Senior Non-Executive Chairman of the Board
Hafrun Fridriksdottir
President - US, Chief R&D Officer
Helen Middlemist
Company Secretary
Ali K. Al-Husry
Non-Executive Director
Laura Balan
Designated Non-Executive Independent Director - Workforce Engagement
Cynthia L. Flowers
Non-Executive Independent Director
Douglas Malcolm Hurt
Senior Non-Executive Independent Director
Said Samih Darwazah
Chief Executive Officer, Executive Director
Mazen Samih Talib Darwazah
Executive Vice Chairman of the Board, Deputy Chief Executive Officer of MENA
Hussein Arkhagha
Chief People Officer
Susan Ringdal
Executive Vice President - Strategic Planning and Global Affairs
Bassam Wael Roshdi Kanaan
Chief Financial Officer, Executive Vice President
Julie Hill
Senior Vice President - Corporate Quality Compliance and Health and Safety
Sam Park
Group General Counsel
Khalid Nabilsi
Deputy Chief Executive Officer - North America and Europe, Executive Director
Click to see more

Key facts

  • Shares in issue
    223.56m
  • EPIC
    HIK
  • ISIN
    GB00B0LCW083
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    £3.29bn
  • Employees
    9,603
  • Exchange
    London Stock Exchange (LON)
  • Index
    FTSE All Share Index, Britain-FTSE250-Index, FTSE 100 Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.